Sign in
CompletedPhase 1/2

Montmorency Cherry Supplementation, Sleep, and Inflammation

Key facts

Who runs it
Michigan State University
Where
East Lansing, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 1/2
People taking part
34 people enrolled
Started
18 Feb 2023
Ended
17 Apr 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Montmorency cherry supplement
  • Control
Record updated
8 September 2025

Who can take part

Age
18 years to 50 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • body mass index (BMI) of ≥ 25.0 kg/m2
  • sleep issues as identified by a global score of 5 or greater on the Pittsburgh Sleep Quality Index (PSQI) and/or a score 8 or higher on the Insomnia Severity Index (ISI)
  • ability to adhere to a diet low in antioxidants during the study period; and
  • willingness to wear a Fitbit for the duration of the study and to wear the Zmachine on selected nights

Who cannot take part

  • unwilling or unable to stop the use of sleep medication
  • unable to attend laboratory visits on the East Lansing, Michigan campus

Where in United States

  • Michigan State UniversityEast Lansing, United States

About the trial

What the trial wants to find out

This study will test the effects of Montmorency cherry supplementation on sleep outcomes and inflammatory biomarkers.

The 2 groups in the trial

  • InterventionTreatment being tested

    500 mg cherry supplement

    Treatment: Montmorency cherry supplement

  • ControlPlacebo, for comparison

    Placebo

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effects of Montmorency Cherry Supplementation on Sleep and Inflammatory Outcomes
Record updated
8 September 2025